<DOC>
	<DOCNO>NCT00864266</DOCNO>
	<brief_summary>The primary aim study identify predictive molecular signature response chemotherapy , accord WHO criterion , patient non-small cell lung cancer study transcriptome ( miRNAs mRNAs ) single nucleotide polymorphism ( SNPs ) use high throughput technique .</brief_summary>
	<brief_title>Biological Factors Predicting Response Chemotherapy Advanced Non Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>Histological diagnosis nonsmallcell lung cancer ( NSCLC ) Obtention biopsy tumour accord procedure define protocol NSCLC stage treat standard conventional firstline chemotherapy , define ELCWP guideline ( www.elcwp.org ) Presence least one assessable lesion Availability participate detailed followup protocol Signed informed consent . Age 18 year Patient previously treat chemotherapy NSCLC contraindication preclude administration conventional chemotherapy NSCLC NSCLC treat exclusive surgery radiotherapy A history prior malignant tumour , except nonmelanoma skin cancer situ carcinoma cervix bladder cure malignant tumour ( 5year disease free interval )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Non small cell lung carcinoma</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Response prediction</keyword>
</DOC>